Sugi Predict

Sugi Predict / Compounds / SCHEMBL1991037

SCHEMBL1991037

SCHEMBL1991037

N#Cc1cc2cnc(Cl)nc2n1C1CCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 8/20 0.48
▸ CTSS P25774 7/20 0.48
▸ CDK2 P24941 5/20 0.47
▸ CDK1 P06493 3/20 0.47
▸ AURKA O14965 1/20 0.46
▸ AURKB Q96GD4 1/20 0.46
▸ NUAK1 O60285 3/20 0.40
▸ CDK4 P11802 6/20 0.37
▸ CCND1 P24385 6/20 0.37
▸ CCNT1 O60563 4/20 0.37
▸ CDK9 P50750 4/20 0.37
▸ CCNE1 P24864 3/20 0.37
▸ CDK6 Q00534 3/20 0.37
▸ CCNA2 P20248 2/20 0.37
▸ PIK3CD O00329 1/20 0.37
▸ PRKAB2 O43741 1/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ FYN P06241 1/20 0.37
▸ CSF1R P07333 1/20 0.37
▸ RET P07949 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22860084 0.82 NUAK1 (0.59) CTSKCTSSCDK2CDK1NUAK1
SCHEMBL4189989 0.78 CCNT1 (0.42) CTSKCTSSCDK2CDK4CCND1
SCHEMBL20676931 0.78 CCND1 (0.42) CTSKCTSSCDK2CDK4CCND1
SCHEMBL6364400 0.78 CDK4 (0.46) CTSKCTSSCDK2CDK1AURKA
SCHEMBL31475403 0.76 CDK2 (0.57) CDK2NUAK1CDK4CCND1CCNT1
SCHEMBL2685547 0.75 CTSK (0.48) CTSKCTSSCDK2CDK1AURKA
SCHEMBL27927200 0.75 NUAK1 (0.40) CTSKCTSSCDK2NUAK1CDK4
SCHEMBL1993255 0.75 CTSK (0.41) CTSKCTSSCDK2CDK4CCND1
SCHEMBL6363390 0.75 CTSK (0.48) CTSKCTSSCDK2CDK1AURKA
SCHEMBL34467973 0.74 JAK2 (0.37) CTSKCTSSCDK2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146042-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2026-05-28 — — US disclosed
CN-117720532-A Pyrrolopyrimidine derivatives as RSK inhibitors and use thereof 华东师范大学 2024-03-19 — — CN disclosed
US-20240043428-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES ASTEX THERAPEUTICS LTD. (GB) 2024-02-08 — — US disclosed
US-20210253578-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES ASTEX THERAPEUTICS LTD. (GB) 2021-08-19 — — US disclosed
US-20210253578-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES ASTEX THERAPEUTICS LTD. (GB) 2021-08-19 — — US disclosed
US-20180155351-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2018-06-07 — — US disclosed
US-20180155351-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2018-06-07 — — US disclosed
US-20180155351-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2018-06-07 — — US disclosed
US-20170183352-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2017-06-29 — — US disclosed
US-20170183352-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2017-06-29 — — US disclosed
CN-102186856-A Pyrrolopyrimidines as CDK inhibitors NOVARTIS AG 2011-09-14 — — CN disclosed
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2011-06-23 — — US disclosed
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2011-06-23 — — US disclosed
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2011-06-23 — — US disclosed
EP-2331547-A1 PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS Novartis AG (CH) 2011-06-15 — — EP disclosed
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG 2010-04-29 — — US disclosed
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG 2010-04-29 — — US disclosed
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG 2010-04-29 — — US disclosed
WO-2010020675-A1 PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS NOVARTIS AG (CH) 2010-02-25 — — WO disclosed
WO-2010020675-A1 PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS NOVARTIS AG (CH) 2010-02-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260146042-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK9, CDK6, CDK7 CTSK 2805/4885CTSS 1517/4885CDK2 9/4885
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 CTSK 1811/4885CTSS 3017/4885CDK2 7/4885
US-20170183352-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 CTSK 1811/4885CTSS 3017/4885CDK2 7/4885
US-20240043428-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 CTSK 1811/4885CTSS 3017/4885CDK2 7/4885
US-20180155351-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 CTSK 1811/4885CTSS 3017/4885CDK2 7/4885
US-20210253578-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 CTSK 1811/4885CTSS 3017/4885CDK2 7/4885
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 CTSK 1811/4885CTSS 3017/4885CDK2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.